Tag : DURVALUMAB

NEWS AND PERSPECTIVE

Durvalumab receives FDA approval for LS-SCLC
Durvalumab, a human monoclonal antibody targeting the programmed death-ligand 1 (PD-L1) protein, has recently been granted the United States Food and Drug Administration (US FDA) approval as the first and only immunotherapy for patients with limited-stage small-cell lung cancer (LS-SCLC) who have not experienced disease progression following concurrent platinum-based chemotherapy and radiation therapy. This approval, based on results from the phase 3 ADRIATIC trial, marks a significant milestone in the treatment of this aggressive form of lung cancer, offering new hope for improved survival outcomes.
INFOGRAPHICS

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC